Novel oral anticoagulants in acute coronary syndrome

International Journal of Cardiology

Volumn 167, Issue 6, 2013, Pages 2449-2455

  Costopoulos, Charis ^a   Niespialowska Steuden, Maria ^a   Kukreja, Neville ^a   Gorog, Diana A ^a,b,c  

^a EandN Hertfordshire NHS Trust   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Acute coronary syndrome; Anticoagulants; Myocardial infarction; Platelet aggregation; Thrombin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ATOPAXAR; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBAMAZEPINE; CLOPIDOGREL; DABIGATRAN; DAREXABAN; FONDAPARINUX; HEPARIN; HIRULOG; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PHENOBARBITAL; PHENYTOIN; PLACEBO; POSACONAZOLE; RIFAMPICIN; RIVAROXABAN; THROMBIN INHIBITOR; UNINDEXED DRUG; VORAPAXAR; VORICONAZOLE; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DEVELOPING COUNTRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG WITHDRAWAL; EMBOLISM; EVIDENCE BASED PRACTICE; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; MORBIDITY; MORTALITY; PANDEMIC; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ACS; ACUTE CORONARY SYNDROME; AF; AN EFFICACY AND SAFETY STUDY FOR RIVAROXABAN IN PATIENTS WITH ACUTE CORONARY SYNDROME; ANTI-XA THERAPY TO LOWER CARDIOVASCULAR EVENTS IN ADDITION TO ASPIRIN WITH OR WITHOUT THIENOPYRIDINE THERAPY IN SUBJECTS WITH ACUTE CORONARY SYNDROME-THROMBOLYSIS IN MYOCARDIAL INFARCTION 46; ANTICOAGULANTS; APIXABAN FOR PREVENTION OF ACUTE ISCHAEMIC AND SAFETY EVENTS TRIAL; APIXABAN FOR PREVENTION OF ACUTE ISCHAEMIC EVENTS 2 TRIAL; APPRAISE; APPRAISE-2; ATLAS ACS-TIMI 46; ATLAS ACS-TIMI 51; ATRIAL FIBRILLATION; CAD; CLOPIDOGREL IN UNSTABLE ANGINA TO PREVENT RECURRENT EVENTS; CORONARY ARTERY DISEASE; CRCL; CREATININE CLEARANCE; CURE; DAPT; DOSE FINDING STUDY FOR DABIGATRAN ETEXILATE IN PATIENTS WITH ACUTE CORONARY SYNDROME; DUAL ANTI-PLATELET THERAPY; FACTOR XA INHIBITOR YM150 FOR THE PREVENTION OF BLOOD CLOT FORMATION IN VEINS AFTER SCHEDULED HIP REPLACEMENT; GLOBAL USE OF STRATEGIES TO OPEN OCCLUDED CORONARY ARTERIES; GUSTO; HAZARD RATIO; HR; INTERNATIONAL SOCIETY OF THROMBOSIS AND HAEMOSTASIS; ISTH; J-LANCELOT-ACS; LANCELOT-ACS; LESSON FROM ANTAGONIZING THE CELLULAR EFFECTS OF THROMBIN-ACUTE CORONARY; LMWH; LOW MOLECULAR WEIGHT HEPARINS; MACE; MAJOR ADVERSE CARDIAC EVENTS; MI; MYOCARDIAL INFARCTION; NON-ST-ELEVATION MYOCARDIAL INFARCTION; NSTEMI; ONYX-2 TRIAL; PAR 1; PCI; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PROTEASE-ACTIVATED RECEPTOR 1; RANDOMIZED EVALUATION OF LONG TERM ANTICOAGULANT THERAPY (RE-LY) WITH DABIGATRAN ETEXILATE; RE-DEEM; RE-LY; RIVAROXABAN VERSUS WARFARIN IN NON-VALVULAR ATRIAL FIBRILLATION TRIAL; ROCKET AF; RUBY-1 TRIAL; SAFETY AND TOLERABILITY OF E5555 AND ITS EFFECTS ON MARKERS OF INTRAVASCULAR INFLAMMATION IN SUBJECTS WITH CORONARY ARTERY DISEASE; STUDY EVALUATING SAFETY, TOLERABILITY AND EFFICACY OF YM150 IN SUBJECTS WITH ACUTE CORONARY SYNDROMES; THROMBIN; THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME; THROMBOLYSIS IN MYOCARDIAL INFARCTION DEFINITION; TIMI; TRACER; VENOUS THROMBOEMBOLISM; VITAMIN K ANTAGONIST; VKA; VTE;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES;

EID: 84883749171     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.08.014     Document Type: Review

References (51)

1. R.P. Giugliano, and E. Braunwald The year in non-ST-segment elevation acute coronary syndrome J Am Coll Cardiol 58 2011 2342 2354
2. P.R. Moreno, E. Falk, I.F. Palacios, J.B. Newell, V. Fuster, and J.T. Fallon Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture Circulation 90 1994 775 778
3. R. Ross Atherosclerosis-an inflammatory disease N Engl J Med 34 1999 115 126
4. S.R. Coughlin Thrombin signalling and protease-activated receptors Nature 407 2000 258 264
5. J.R. Hamilton Protease-activated receptors as targets for antiplatelet therapy Blood Rev 23 2009 61 65
6. K.A. Fox, F.A. Anderson Jr., and S.G. Goodman Time course of events in acute coronary syndromes: Implications for clinical practice from the GRACE registry Nat Clin Pract Cardiovasc Med 5 2008 580 589
7. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
8. C.W. Hamm, J.P. Bassand, and S. Agewall ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
9. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during instability in coronary artery disease (FRISC) study group Lancet 347 1996 561 568
10. M. Hurlen, M. Abdelnoor, P. Smith, J. Erikssen, and H. Arnesen Warfarin, aspirin, or both after myocardial infarction N Engl J Med 347 2002 969 974
11. R. Sørensen, M.L. Hansen, and S.Z. Abildstrom Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 2009 1967 1974
12. J. Hirsh Oral anticoagulant drugs N Engl J Med 324 1991 1865 1875
13. J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 2004 204S 233S
14. L. Wallentin, R.G. Wilcox, and W.D. Weaver Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797
15. Eliquis Prescribing Information http://www.eliquis.com/PDF/ ELIQUIS®SmPC.pdf
16. C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation NEJM 365 2011 981 992
17. M.R. Lassen, A.S. Gallus, G.F. Pineo, and G.E. Raskob LB-MO-005 Late breaking clinical trial: The ADVANCE - 2 study: A randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement Presented at XXII Congress of the International Society on Thrombosis and Hemostasis July 11-16 2009 [Boston, MA.]
18. J.H. Alexander, R.C. Becker, and D.L. Bhatt Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial Circulation 119 2009 2877 2885
19. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
20. J.H. Alexander, R.D. Lopes, and S. James APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome NEJM 365 2011 699 708
21. Xarelto Prescribing Information http://www.drugs.com/pro/xarelto.html
22. R. Bauersachs, S.D. Berkowitz, and B. Brenner Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
23. H. Wong, N. Nunokawa, and J.C. Song 'Rivaroxaban: A Direct Factor Xa Inhibitor for VTE Prophylaxis in Patients Undergoing Total Knee or Hip Replacement Surgery.' Formulary 44 2009 226 236
24. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation NEJM 365 2011 883 891
25. J.L. Mega, E. Braunwald, and S. Mohanavelu Rivaroxaban versus placebo in patients with acute coronary syndromes (Atlas Acs-Timi 46): a randomised, double-blind, phase II trial Lancet 374 2009 29 38
26. J.L. Mega, E. Braunwald, and S.D. Wiviott ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome NEJM 366 2012 9 19
27. M. Heeringa, D. Groenendaal, and G. Strabach Co-administration of darexaban (YM150), an oral direct factor Xa inhibitor, with acetylsalicylic acid, clopidogrel and naproxen: no evidence of clinically relevant interactions J Thromb Hemost 9 Suppl. 2 2007 360
28. M. Heeringa, D. Groenendaal, and G. Strabach The pharmacokinetics of YM150, an oral direct factor Xa inhibitor, are not affected to a clinically relevant degree by strong inhibition or induction of CYP3A4 and P-gp J Thromb Hemost 9 Suppl. 2 2011 359 360
29. B.I. Eriksson, A.G.G. Turpie, and M.R. Lassen ONYX-2 STUDY GROUP. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2) J Thromb Haemost 8 2010 714 721
30. Astellas Pharma Europe BV. A study evaluating safety and tolerability of YM150 compared to warfarin in subjects with atrial fibrillation (OPAL-2). Astellas Pharma Inc. Clinicaltrials.gov identifier: NCT00938730. Available at: http://clinicaltrials.gov/ct2/show/NCT00938730?term=NCT00938730&rank=1.
31. P.G. Steg, S.R. Mehta, and J.W. Jukema RUBY-1 Investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome Eur Heart J 32 2011 2541 2554
32. J. Stangier, K. Rathgen, H. Stahle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303
33. Pradaxa Prescribing Information - Boehringer Ingelheim http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf
34. S.H. Schirmer, M. Baumhakel, and H.R. Neuberger Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments J Am Coll Cardiol 56 2010 2067 2076
35. S. Schulman, C. Kearon, and A.K. Kakkar Dabigatran versus warfarin in the treatment of acute venous thromboembolism NEMJ 361 2009 2342 2352
36. L. Wallentin, S. Yusuf, and M.D. Ezekowitz Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the Re-Ly trial Lancet 376 2010 975 983
37. J. Oldgren, A. Budaj, and C.B. Granger RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 2781 2789
38. C. Christersson, J. Oldgren, A. Bylock, A. Siegbahn, and L. Wallentin Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial Eur Heart J 28 2007 692 698
39. J.M. Siller-Matula, J. Krumphuber, and B. Jilma Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases Br J Pharmacol 15 2010 502 517
40. R.C. Becker, D.J. Moliterno, and L.K. Jennings TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 373 2009 919 928
41. S. Goto, T. Yamaguchi, Y. Ikeda, K. Kato, H. Yamaguchi, and P. Jensen Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome J Atheroscler Thromb 17 2010 156 164
42. P. Tricoci, Z. Huang, and C. Held TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes NEMJ 366 2012 20 33
43. M.L. O'Donoghue, D.L. Bhatt, and S.D. Wiviott LANCELOT-ACS Investigators. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial Circulation 123 2011 1843 1853
44. S. Goto, H. Ogawa, M. Takeuchi, M.D. Flather, and D.L. Bhatt J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease Eur Heart J 31 2010 2601 2613
45. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
46. J. van Ryn, J. Stangier, and S. Haertter Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
47. E. Lindhoff-Last, M.M. Samama, T.L. Ortel, J.I. Weitz, and T.E. Spiro Assays for measuring rivaroxaban: their suitability and limitations Ther Drug Monit 32 2010 673 679
48. Y.C. Barrett, Z. Wang, C. Frost, and A. Shenker Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay Thromb Haemost 104 2010 1263 1267
49. S. Hariharan, and R. Madabushi Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment J Clin Pharmacol 52 2012 119S 125S
50. S. Wiviott, E. Braunwald, and C. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes NEMJ 357 2007 2001 2015
51. L. Wallentin, R.C. Becker, and A. Budaj for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes NEMJ 361 2009 1045 1057